Trial Profile

A domestic Phase 3 multicenter, single-arm, open-label study evaluating the safety and immunogenicity of Tycovac aqueous suspension intramuscular injection in healthy Japanese adults aged 16 years and older and Japanese children aged 1 year to 16 years

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Apr 2024 New trial record
26 Mar 2024 According to Pfizer media release, the company has applied for manufacturing and sales approval for this drug to the Ministry of Health, Labor and Welfare in March 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com